课题基金 / 基金详情

NA & H EXCHANGE INHIBITOR HOE 642 ON ALL CAUSE MORTALITY & MYOCARDIAL

NA & H EXCHANGE INHIBITOR HOE 642 ON ALL CAUSE MORTALITY & MYOCARDIAL
不适用
批准号：
6264885
负责人：
Robert Charles Detrano
金额：
$0.1万
依托单位：
LUNDQUIST INSTITUTE FOR BIOMEDICAL INNOVATION AT HARBOR-UCLA MEDICAL CENTER
依托单位国家：
美国
项目类别：
财政年份：
1998
资助国家：
美国
项目状态：
已结题
起止时间：
1998-12-01 至 1999-11-30
来源：
https://reporter.nih.gov/project-details/6264885
关键词：
clinical research disease /disorder proneness /risk drug /agent heart disorder human mortality human subject

项目摘要

项目成果

Robert Charles Detrano的其他基金

相关文献

中文摘要
翻译
确定HOE642治疗是否会降低心脏损伤的风险，并减少致命结果的数量。将研究三组患者：1)胸痛，2)计划冠状动脉扩张，3)计划冠状动脉搭桥。病人的任何药物都不会停药。受试者将随机接受HOE642 20、80mg或120mg或安慰剂。在输注前和输注过程中，将采集生命体征和一些血液和尿液样本
英文摘要
To determine if treatment with HOE642 will reduce the amount of risk of heart damage and also reduce the number of fatal outcomes. Three groups of patients will be studied: 1) chest pain, 2) scheduled for coronary artery dilatation, 3) scheduled for coronary artery bypass. None of the patient's medications will be stopped. Subjects will be randomized to receive HOE642 20, 80mg or 120mg or placebo. Prior to the infusion and during the infusion vital signs and several samples of blood and urine will be taken
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
LONG TERM EFFECTS OF SUBCLINICAL CAD ON CARDIAC FUNCTION
LONG TERM EFFECTS OF SUBCLINICAL CAD ON CARDIAC FUNCTION
LONG TERM EFFECTS OF SUBCLINICAL CAD ON CARDIAC FUNCTION
PROGRESSION CORONARY CALCIUM (SBHW)